News
New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in ...
Long COVID also known as post-acute COVID-19 syndrome or PASC refers to the lingering symptoms and health complications that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback